For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a genuine breakthrough . These innovative therapies protect the transthyretin protein, preventing its destructive build-up and lessening the impact of the condition . People are now s